The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

BOSTON —Small interfering RNA technology has the potential to become a novel treatment approach in cardiovascular medicine, according to Clyde W. Yancy, MD, MSc, MACP, MACC, FAHA, FHFSA. In this ...

Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...

Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often ...

Small interfering RNA (siRNA) is a class of double-stranded RNA molecules, typically 20-25 base pairs in length, that play a crucial role in the RNA interference (RNAi) pathway. siRNAs are involved in ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in ...